Clinical trials: Coronary Artery Stenosis Stent
Coronary Stenosis, Coronary Disease
IRIS-Firehawk® Cohort in the IRIS-DES Registry
The objective of this study is to evaluate effectiveness and safety of Firehawk® stent in the "real world" daily practice as compared with other drug-eluting stents.
- Trial name
- IRIS Firehawk (NCT03380286)
- Testing
- Firehawk
- Where
- South Korea
- Sponsor
- Duk-Woo Park, MD
Coronary Stenosis
FrActional Flow Reserve Guided Drug Coated Balloon Only Strategy in De Novo coronarY Lesions (FADDY)
Drug-eluting stent (DES) has been the primary choice for in suit coronary lesions treatment. In comparison to bare-metal stent (BMS), it evidently decreases the rate of restenosis.
- Trial name
- FADDY (NCT03452904)
- Testing
- Drug-coated balloon, Drug-eluting stent
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Coronary Artery Stenosis, Coronary Arteriosclerosis
XIENCE V: SPIRIT WOMEN
The purpose of this Clinical Evaluation is the continued assessment of the XIENCE Everolimus Eluting Coronary Stent System (XIENCE V® and XIENCE PRIME™ EECSS) with the primary focus on clinical outcomes in the treatment of female…
- Conditions
- Coronary Artery Stenosis, Coronary Arteriosclerosis, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT00496938
- Testing
- XIENCE V®/ XIENCE PRIME™
- Where
- 95 sites in Argentina, Australia and 24 more
- Volunteers
- 1,600 people
- Sponsor
- Abbott Medical Devices
Disease Management, Diabetes Complications
Determining Rates of Cardiovascular Complications Among Patients of a Managed Diabetes Care Program
The primary objective of this study is to identify whether cardiovascular complication rates are lower in patients who participate in managed diabetes care, in comparison to provincial and national rates.
- Conditions
- Disease Management, Diabetes Complications, Diabetic Vascular Complications, Diabetic Neuropathy
- Trial name
- DECIDE (NCT00498147)
- Testing
- ADEC Program
- Where
- Canada
- Volunteers
- 1,213 people
- Sponsor
- Group Health Centre
Stable Angina, Coronary Stenosis
Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty
We aimed to evaluate feasibility and the 6-month angiographic and OCT results of FFR - guided use of paclitaxel-eluting balloons (Sequent Please™, B Braun) with provisional bare metal stenting for elective PCI of de novo coronary…
- Trial name
- OCTOPUS-2 (NCT02120859)
- Testing
- FFR - guided DEB angioplasty, Provisional bare metal stenting
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Jena
Coronary Artery Disease
The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial
The ASPECT study is an Asian multicenter, randomized, controlled, triple-blinded study designed to evaluate the ability of the Cook Incorporated Paclitaxel Eluting Supra G Coronary Stent to reduce restenosis in the coronary…
- Trial name
- NCT00196079
- Testing
- Coronary stent
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Cook Group Incorporated
Coronary Stenosis, Coronary Disease
BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
Device: EluNIR Ridaforolimus Eluting Coronary Stent System - (hereafter referred to as EluNIR) 2.25 mm diameter (8 mm, 12 mm, 15 mm, 17 mm, 20 mm, 24 mm, 28 mm and 33 mm length) Objectives: To further assess the safety and…
- Conditions
- Coronary Stenosis, Coronary Disease, Myocardial Ischemia, Cardiovascular Diseases
- Trial name
- NCT04761939
- Testing
- EluNIR Ridaforolimus Eluting Coronary Stent System
- Where
- 9 sites in Israel
- Volunteers
- 81 people
- Sponsor
- Medinol Ltd.
Stent Thrombosis, Coronary Artery Disease
CONNECT DES Registrty
To date, drug-eluting stents (DES) have become the standard of care in daily practice for the treatment of ischemic heart disease, by overcoming the risk of in-stent restenosis, a major issue raised in the bare-mare stents era.
- Conditions
- Stent Thrombosis, Coronary Artery Disease, Stent Stenosis, Myocardial Infarction
- Trial name
- NCT04715594
- Testing
- 1st-generation drug-eluting stent, 2nd-generation drug-eluting stents
- Where
- South Korea
- Volunteers
- 350,000 people
- Sponsor
- Yonsei University
Coronary Stenosis, Diabetes Mellitus
Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients
The aim of the study is to compare the efficacy of Paclitaxel-eluting PTCA-balloon dilation (SeQuentTM Please) followed by cobalt-chromium stent (CoroflexTM Blue) deployment versus Paclitaxel-eluting stent (TaxusTM LibertéTM)…
- Trial name
- PEPCAD IV (NCT00462631)
- Testing
- Paclitaxel Eluting Balloon, paclitaxel eluting stent, bare metal stent
- Where
- Malaysia
- Volunteers
- 84 people
- Sponsor
- Heart Centre Rotenburg
Stable Angina, Unstable Angina
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems…
- Conditions
- Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction
- Trial name
- HOST-IDEA (NCT02601157)
- Testing
- 3-months DAPT, 1-year DAPT
- Where
- 12 sites in South Korea
- Volunteers
- 2,173 people
- Sponsor
- Seoul National University Hospital
Angioplasty, Chronic Coronary Occlusion
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort…
- Conditions
- Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease
- Trial name
- XV CHINA SAS (NCT01249027)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
- Where
- United States
- Volunteers
- 2,605 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Myocardial Ischemia
AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population
Prospective, Randomized (2:1), active control, single-blind, non-inferiority, multicenter, Japanese Clinical Trial to evaluate the safety and effectiveness of Absorb™ BVS (AVJ-301) in the treatment of subjects with ischemic heart…
- Trial name
- ABSORB JAPAN (NCT01844284)
- Testing
- XIENCE PRIME®/XIENCE Xpedition™, Absorb™ BVS
- Where
- 39 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Hydroxyapatite Active Pro Healing Clinical Trial Program
The purpose of this first feasibility study is to evaluate the performance of Vesta™ \& VestaCOR™ (Hydroxy-Apetite coated GenX) stent in de novo native coronary artery lesions.
- Trial name
- HApFIM (NCT00474084)
- Testing
- Intravascular Coronary Stent
- Volunteers
- 70 people
- Sponsor
- BioSync Scientific Pvt. Ltd.
Coronary Artery Disease
The Nordic-Baltic Bifurcation Study IV
How should coronary artery stenoses with significant side branch be stented? A strategy of stenting both main vessel and side branch compared to a strategy of stenting the main vessel and only stenting the side branch if…
- Trial name
- BIF IV (NCT01496638)
- Testing
- Implantation of coronary stent in bifurcation lesion
- Where
- Denmark
- Volunteers
- 450 people
- Sponsor
- Evald Hoej Christiansen
Coronary Artery Disease, Coronary Stenosis
TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment
The aim of the TARGET PREMIER trail in to demonstrate the safety and efficacy of the rapamycin target eluting stent in the treatment of subjects with ischemic heart disease (asymptomatic myocardial ischemia , table or unstable…
- Trial name
- T-P (NCT04951050)
- Testing
- Rapamycin target eluting stent
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Stenosis
Coronary Artery Stent Evaluation With 320-slice Computed Tomography - The CArS 320 Study
The investigators aim at analyzing the diagnostic accuracy of 320-row CT for coronary stents.
- Trial name
- CARS-320 (NCT00967876)
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Charite University, Berlin, Germany
de Novo, Symptomatic Ischemic Heart Disease
BIOFLOW-SV All Comers Registry
Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm.
- Conditions
- de Novo, Symptomatic Ischemic Heart Disease, Restenoses, Coronary
- Trial name
- BIOFLOW-SV (NCT03600948)
- Testing
- Orsiro Sirolimus Eluting Coronary Stent System
- Where
- 2 sites in Brazil
- Volunteers
- 261 people
- Sponsor
- Biotronik AG
Coronary Stenosis
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
The study will enroll approximately 316 subjects with a wide spectrum of PCI indications (stable angina as well as ACS), who are considered to be at high risk of bleeding.
- Trial name
- NCT03877848
- Testing
- Percutaneous Coronary Intervention (PCI)
- Where
- Israel
- Volunteers
- 319 people
- Sponsor
- Medinol Ltd.
Coronary Artery Disease, Angina Pectoris
DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity
Rationale: The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity but there are further demands on DES performance.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Unstable Angina Pectoris, Acute Coronary Syndrome
- Trial name
- DUTCHPEERS (NCT02175706)
- Testing
- Resolute Integrity®, Promus Element®
- Where
- 4 sites in Netherlands
- Volunteers
- 1,811 people
- Sponsor
- Thorax Centrum Twente
Coronary Disease, Coronary Artery Disease
SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe
The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT V (NCT00402272)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 93 sites in Austria, Belgium and 21 more
- Volunteers
- 2,700 people
- Sponsor
- Abbott Medical Devices